HD-OPM Archive
Topics › Inflammation & CRP

Colchicine may work partly by inhibiting IL-11, a lifespan-linked pro-fibrotic cytokine

Louis Nervegna · Jul 26, 2024 · ♥ 13 reactions · 15 comments · original Facebook post
Inflammation & CRPAging & longevity
AI summary & key facts

The poster speculates that because colchicine, the first approved anti-inflammatory heart drug, has anti-fibrotic effects (it was studied in pulmonary fibrosis), it may act partly through IL-11 inhibition. Blocking IL-11 extended mouse lifespan by 25%, and anti-IL-11 therapies are entering pulmonary fibrosis trials. This is a hypothesis.

Colchicine was the first drug approved to treat heart disease by targeting inflammation.

Colchicine has anti-fibrotic properties, e.g. in the lungs.

This hints that it may actually be working, in part, by inhibiting IL-11. This is a big deal because blocking IL-11 extends lifespan of mice by 25%.

The main company working on anti-IL-11 therapies in humans is beginning trials in pulmonary fibrosis.

It may not be a coincidence that colchicine has been previously investigated as a treatment for pulmonary fibrosis.

#colchicineHD #il11HD #inflammationHD

Paper · Chest · 1993Colchicine in the Treatment of Pulmonary FibrosisThere is no standard or known optimal treatment for idiopathic pulmonary fibrosis. Corticosteroids have been used with widely variable benefit. Colchisciencedirect.com

Research cited

← newer: Meta-analysis of 69 RCTs: protein strength gains plateau at older: A normal coronary CTA can still miss early wall plaque that →